Polyurethanes and childhood asthma

Cheryl A Krone1, Tom D Klingner, John T Ely

  • 1Applied Research Institute, Palmerston North, New Zealand.

Insights

Neonatal exposure to isocyanates from polyurethane medical materials may contribute to childhood asthma. Dermal contact with these materials can lead to sensitization and immune system dysregulation in infants.

Area of Science:

  • Pediatric Allergy and Immunology
  • Environmental Health
  • Neonatal Medicine

Background:

  • Childhood asthma prevalence is increasing, with genetic and environmental factors implicated.
  • Early-life exposure to environmental stressors can disrupt immune system balance.
  • Isocyanates, used in polyurethane production, are known to trigger asthma and atopy-like immune responses.

Purpose of the Study:

  • To investigate potential neonatal exposure to isocyanates via polyurethane-containing medical materials.
  • To explore the link between early-life dermal exposure to isocyanates and the development of childhood asthma.

Main Methods:

  • Surveyed polyurethane-containing medical materials in a neonatal unit.
  • Tested material samples for isocyanate residues using a colorimetric method.

Main Results:

  • Isocyanate residues were detected in various neonatal medical materials, including wound dressings and adhesive films.
  • These materials directly contact neonatal skin.

Conclusions:

  • Neonates may experience dermal exposure to isocyanates through polyurethane medical materials.
  • Dermal isocyanate exposure can cause sensitization and asthma in animal models.
  • This exposure may contribute to immune system dysregulation and predispose infants to childhood asthma.
Abstract

Related Concept Videos

Asthma I: Introduction01:28

Asthma I: Introduction

Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
Asthma-I: Introduction01:29

Asthma-I: Introduction

Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics01:23

Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics

Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla.  Benzonatate operates peripherally within the respiratory tract by anesthetizing...